600511.SS Stock Analysis
60
Neutral
Based on Eyestock quantitative analysis, 600511.SS`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Undervalued
China National Medicines Co., Ltd. engages in the manufacturing and distribution of pharmaceuticals. The company is headquartered in Beijing, Beijing and currently employs 3,005 full-time employees. The company went IPO on 2002-11-27. The firm's primary products include proprietary Chinese medicines, chemical medicine preparations, chemical raw materials, antibiotics, biochemical drugs, biological products, narcotic drugs, psychotropic drugs, vaccines and health foods, among others. The firm is also involved in the production of pharmaceuticals and the provision of warehousing services through its subsidiaries.